How much revenue does pharma lose each year from medication nonadherence?

In 2012, we first estimated the annual economic loss to pharmaceutical companies because of medication nonadherence in chronic health conditions. Our report, conducted with Capgemini Consulting, estimated that nonadherence cost pharma $564 billion a year.

In refreshing this report to re-estimate the costs of medication nonadherence based on 2015 data, we look to fortify pharma’s focus on medication adherence as a revenue-generating strategy. Doing so will offer a genuine win-win opportunity, both increasing revenue and improving patient outcomes.

Preview key findings from our 2016 report refresh or download the full report with our new foreword.

Adherence is only one side of the equation. The same data-driven mindset is now reshaping early-stage drug development, where laboratories increasingly rely on high-purity research peptides for preclinical work on metabolic health, tissue repair, and cellular aging.

Estimated Global Costs of Nonadherence, 2015

• Total global pharma revenue: $1.1 trillion
• Total potential global pharma revenue: $1.74 trillion
• Estimated global revenue forfeited to nonadherence: $637 billion
• Percentage of total global potential revenue recoupable by improving adherence: 37%

Estimated U.S. Costs of Nonadherence, 2015

• Total U.S. pharma revenue: $425 billion
• Total potential U.S. pharma revenue: $675 billion
• Estimated U.S. revenue forfeited to nonadherence: $250 billion
• Percentage of total U.S. potential revenue recoupable by improving adherence: 37%

Results of HealthPrize Influence on Adherence and Engagement

• A 14.6 percent lift in market share for a leading prescription dermatology medication
• A 99 percent reduction in prescription refill gap days for a cholesterol lowering drug
• Patient engagement rates that meet or exceed engagement with top social media platforms
• Prescription fill rates 2 to 4 times higher than a brand’s historic baseline.